Novartis Inks Deal with Molecular Partners for a Novel Way to Take Down COVID-19
By T. Chakraborty, Ph.D. Pharma giant Novartis is spending $69 million upfront to acquire two experimental drugs (MP0420 and MP0423) from Molecular Partners (MP) for combatting COVID-19. The drugs which …
Read More